The stock of Harvard Bioscience, Inc. (NASDAQ:HBIO) hit a new 52-week low and has $2.07 target or 12.00% below today’s $2.35 share price. The 8 months bearish chart indicates high risk for the $78.96 million company. The 1-year low was reported on Nov, 2 by Barchart.com. If the $2.07 price target is reached, the company will be worth $9.48 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock last traded at $2.35 per share. It is down 22.19% since March 31, 2016 and is downtrending. It has underperformed by 24.71% the S&P500.
Analysts await Harvard Bioscience, Inc. (NASDAQ:HBIO) to report earnings on November, 3. They expect $0.01 earnings per share, down 50.00% or $0.01 from last year’s $0.02 per share. HBIO’s profit will be $336,000 for 58.75 P/E if the $0.01 EPS becomes a reality. After $0.01 actual earnings per share reported by Harvard Bioscience, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
According to Zacks Investment Research, “HARVARD BIOSCIENCE develops, manufactures and markets tools used in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories.”
Insitutional Activity: The institutional sentiment decreased to 0.76 in Q2 2016. Its down 0.27, from 1.03 in 2016Q1. The ratio is negative, as 13 funds sold all Harvard Bioscience, Inc. shares owned while 32 reduced positions. 17 funds bought stakes while 17 increased positions. They now own 22.70 million shares or 4.80% less from 23.85 million shares in 2016Q1.
Bard Associate Inc holds 0.55% or 365,325 shares in its portfolio. Spark Invest Lc accumulated 35,000 shares or 0.01% of the stock. Renaissance Tech holds 0% of its portfolio in Harvard Bioscience, Inc. (NASDAQ:HBIO) for 534,200 shares. United Automobile Association reported 235,452 shares or 0% of all its holdings. Blackrock Gp Limited holds 0% or 26,421 shares in its portfolio. Ladenburg Thalmann Svcs Incorporated last reported 300 shares in the company. Segall Bryant And Hamill Limited holds 337,281 shares or 0.03% of its portfolio. First Light Asset Limited Liability Co holds 2.74M shares or 3.63% of its portfolio. Jupiter Asset Management Limited holds 0.1% of its portfolio in Harvard Bioscience, Inc. (NASDAQ:HBIO) for 874,248 shares. Jbf Capital Inc reported 6,200 shares or 0% of all its holdings. Glacier Peak Capital Limited Liability Company reported 446,707 shares or 1.35% of all its holdings. Jane Street Lc reported 20,011 shares or 0% of all its holdings. Diam Limited owns 25,705 shares or 0% of their US portfolio. Blackrock Fund Advisors has 79,697 shares for 0% of their US portfolio. Panagora Asset accumulated 0% or 28,347 shares.
More news for Harvard Bioscience, Inc. (NASDAQ:HBIO) were recently published by: Finance.Yahoo.com, which released: “Harvard Bioscience reports 3Q loss” on October 27, 2016. Twst.com‘s article titled: “Harvard Bioscience Inc.: Harvard Bioscience Schedules Third Quarter 2016 …” and published on October 13, 2016 is yet another important article.
HBIO Company Profile
Harvard Bioscience, Inc., incorporated on October 8, 2000, is a developer, maker and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company’s product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Firm sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company’s products consist of instruments, consumables and systems that are made up of various individual products.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.